The survivorship of revision total hip replacement with severe proximal bone deficiency using a modular taper fluted prosthesis.

Contemporary uncemented femoral revision hip systems have become commonly used over the past decade and have enabled the reconstruction of leg length, offset and anteversion as independent variables through the use of modular junctions. Modular junction failures between the proximal body and distal stem have been described with revision systems, although this is rare. We sought to identify the survivorship of one revision system in a salvage arthroplasty scenario where no host bone support of the modular junction was present. From a series of 136 patients, 15 patients (16 hips) were identified without host bone support of the modular junction with a mean radiological follow up of over 6 years (76 months +/- 35 months). There have been no cases of prosthetic fracture over the follow-up duration, with two revisions performed for reasons of aseptic loosening and infection. The mean BMI of the study group was 30.2 with 78% of the cohort classified as overweight or obese. It is well recognised that, host bone support of the modular junction is preferable, however the satisfactory outcomes over the midterm in these complex patients suggests that modular revision systems remain an option.

Distal femoral replacement - Does length matter? Mid-term results for distal femoral replacements.

BACKGROUND: Review of mid-term results (five years) for tumour and revision arthroplasty surgery using the Stanmore METS® distal femoral replacement. METHODS: Data were collected retrospectively for 90 patients for procedures performed between 2002 and 2019. Kaplan-Meier survivorship for implant was estimated at five years post-op. Endpoints for survivorship analysis included revision for any cause and as per Henderson classification. Log rank test was used to compare implant survival for different categorical variables. Musculo-Skeletal Tumour Society (MSTS) score was used to estimate function. RESULTS: Overall implant survival at five years was 76% (95% CI 66-86). Implants with a short body (<= 45 mm) had significantly better implant survival [87% (95% CI 78-99)] compared to those with larger bodies [63% (95% CI 48-82)] (logrank test, p = 0.031). There was no significant difference in implant survival for tumour and revision arthroplasty patients (logrank test, p = 0.61). Mean MSTS scores (median follow-up = 3.5 years) for tumour and revision arthroplasty patient were 71% and 63% respectively (Wilcoxon rank test, p < 0.05). Higher total number of surgeries was a significant predictor of patient mortality [HR = 0.7 (95% CI 0.49-0.99)]. Longer bodies were a significant predictor of implant failure [HR = 3.2 (95% CI 1.05-10.53), p < 0.05]. CONCLUSION: Overall outcome of Stanmore METS® distal femoral replacement at five years following tumour and revision arthroplasty reconstruction is comparable to the other implants.